tetano
Editor, Senior Moderator
Int Med Case Rep J
. 2023 Sep 15;16:551-559.
doi: 10.2147/IMCRJ.S410806. eCollection 2023. Myocarditis Following Inactivated SARS-CoV-2 Vaccine (Vero Cell) in an Adult Female in Vietnam: A Case Report
Hoa Tran[SUP] 1 [/SUP], Vu Hoang Vu[SUP] 1 [/SUP], Duc Tran[SUP] 2 [/SUP], Quang Dang Duy Pham[SUP] 2 [/SUP], Khang Duong Nguyen[SUP] 2 [/SUP], Binh Quang Truong[SUP] 1 [/SUP]
Affiliations
During the Coronavirus disease 2019 (COVID-19) pandemic, vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has proven to be an important measure to help control disease spread and improve patient outcome. There are four distinct vaccine categories: inactivated viral vaccines, messenger RNA (mRNA) vaccines, adenovirus vector-based vaccines, and adjuvanted protein vaccines. In 2021, increased cases of myocarditis and pericarditis were reported after mRNA and adenovirus vector-based COVID-19 vaccination. A similar reporting pattern has not been observed after receipt of inactivated virus vaccines. Here, we present a case of clinically suspected acute myocarditis in a 26-year-old female, occurring 11 days after the administration of Sinopharm Vero Cell, an inactivated virus COVID-19 vaccine. This event led to acute heart failure, with marked clinical resolution observed within 34 days.
Keywords: COVID-19 vaccine-associated myocarditis; SARS-CoV-2; Vero Cell; inactivated virus COVID-19 vaccine.
. 2023 Sep 15;16:551-559.
doi: 10.2147/IMCRJ.S410806. eCollection 2023. Myocarditis Following Inactivated SARS-CoV-2 Vaccine (Vero Cell) in an Adult Female in Vietnam: A Case Report
Hoa Tran[SUP] 1 [/SUP], Vu Hoang Vu[SUP] 1 [/SUP], Duc Tran[SUP] 2 [/SUP], Quang Dang Duy Pham[SUP] 2 [/SUP], Khang Duong Nguyen[SUP] 2 [/SUP], Binh Quang Truong[SUP] 1 [/SUP]
Affiliations
- PMID: 37732113
- PMCID: PMC10508278
- DOI: 10.2147/IMCRJ.S410806
During the Coronavirus disease 2019 (COVID-19) pandemic, vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has proven to be an important measure to help control disease spread and improve patient outcome. There are four distinct vaccine categories: inactivated viral vaccines, messenger RNA (mRNA) vaccines, adenovirus vector-based vaccines, and adjuvanted protein vaccines. In 2021, increased cases of myocarditis and pericarditis were reported after mRNA and adenovirus vector-based COVID-19 vaccination. A similar reporting pattern has not been observed after receipt of inactivated virus vaccines. Here, we present a case of clinically suspected acute myocarditis in a 26-year-old female, occurring 11 days after the administration of Sinopharm Vero Cell, an inactivated virus COVID-19 vaccine. This event led to acute heart failure, with marked clinical resolution observed within 34 days.
Keywords: COVID-19 vaccine-associated myocarditis; SARS-CoV-2; Vero Cell; inactivated virus COVID-19 vaccine.